RESUMO
The VI European Guidelines for Cardiovascular Prevention recommend combining population and high-risk strategies with lifestyle changes as a cornerstone of prevention, and propose the SCORE function to quantify cardiovascular risk. The guidelines highlight disease specific interventions, and conditions as women, young people and ethnic minorities. Screening for subclinical atherosclerosis with noninvasive imaging techniques is not recommended. The guidelines distinguish four risk levels (very high, high, moderate and low) with therapeutic objectives for lipid control according to risk. Diabetes mellitus confers a high risk, except for subjects with type 2 diabetes with less than <10 years of evolution, without other risk factors or complications, or type 1 diabetes of short evolution without complications. The decision to start pharmacological treatment of arterial hypertension will depend on the blood pressure level and the cardiovascular risk, taking into account the lesion of target organs. The guidelines don't recommend antiplatelet drugs in primary prevention because of the increased bleeding risk. The low adherence to the medication requires simplified therapeutic regimes and to identify and combat its causes. The guidelines highlight the responsibility of health professionals to take an active role in advocating evidence-based interventions at the population level, and propose effective interventions, at individual and population level, to promote a healthy diet, the practice of physical activity, the cessation of smoking and the protection against alcohol abuse.
Assuntos
Doenças Cardiovasculares/prevenção & controle , Estilo de Vida , Guias de Prática Clínica como Assunto , Doenças Cardiovasculares/etiologia , Europa (Continente) , Pessoal de Saúde/organização & administração , Humanos , Adesão à Medicação , Papel Profissional , Fatores de Risco , EspanhaRESUMO
AIMS: To determine the differences between regions in the level of control of patients with non-valvular atrial fibrillation treated with vitamin K antagonists, included in the PAULA study. METHODS: Observational, and coss-sectional/retrospective study, including 139 Primary Care physicians from 99 Health Care centres in all autonomous communities (except La Rioja). Anticoagulation control was defined as the time in therapeutic range assessed by either the direct method (poor control <60%), or the Rosendaal method (poor control <65%). RESULTS: A total of 1,524 patients were included. Small differences in baseline characteristics of the patients were observed. Differences in the percentage of time in therapeutic range were observed, according to the Rosendaal method (mean 69.0±17.7%), from 78.1%±16.6 (Basque Country) to 61.5±14% (Balearic Islands), by the direct method (mean 63.2±17.9%) from 73.6%±16.6 (Basque Country) to 57.5±15.7% (Extremadura). When comparing regions, in those where the Primary Care physicians assumed full control without restrictions on prescription, the percentage of time in therapeutic range by the direct method was 63.89 vs. 60.95% in those with restrictions (p=.006), by Rosendaal method, 69.39% compared with 67.68% (p=.1036). CONCLUSIONS: There are significant differences in the level of control between some regions are still inadequate. Regions in which the Primary Care physicians assumed the management of anticoagulation and without restrictions, time in therapeutic range was somewhat higher, and showed a favourable trend for better control. These findings may have clinical implications, and deserve consideration and specific analysis.
Assuntos
Anticoagulantes/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Médicos de Atenção Primária/estatística & dados numéricos , Vitamina K/antagonistas & inibidores , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Feminino , Humanos , Coeficiente Internacional Normatizado , Masculino , Atenção Primária à Saúde/métodos , Atenção Primária à Saúde/estatística & dados numéricos , Estudos Retrospectivos , Espanha , Fatores de TempoRESUMO
The VI European Guidelines for Cardiovascular Prevention recommend combining population and high-risk strategies with lifestyle changes as a cornerstone of prevention, and propose the SCORE function to quantify cardiovascular risk. The guidelines highlight disease specific interventions, and conditions as women, young people and ethnic minorities. Screening for subclinical atherosclerosis with noninvasive imaging techniques is not recommended. The guidelines distinguish four risk levels (very high, high, moderate and low) with therapeutic objectives for lipid control according to risk. Diabetes mellitus confers a high risk, except for subjects with type 2 diabetes with less than <10 years of evolution, without other risk factors or complications, or type 1 diabetes of short evolution without complications. The decision to start pharmacological treatment of arterial hypertension will depend on the blood pressure level and the cardiovascular risk, taking into account the lesion of target organs. The guidelines don't recommend antiplatelet drugs in primary prevention because of the increased bleeding risk. The low adherence to the medication requires simplified therapeutic regimes and to identify and combat its causes. The guidelines highlight the responsibility of health professionals to take an active role in advocating evidence-based interventions at the population level, and propose effective interventions, at individual and population level, to promote a healthy diet, the practice of physical activity, the cessation of smoking and the protection against alcohol abuse.
Assuntos
Doenças Cardiovasculares/prevenção & controle , Guias de Prática Clínica como Assunto , Adulto , Idoso , Consumo de Bebidas Alcoólicas , Biomarcadores , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Comorbidade , Diabetes Mellitus/epidemiologia , Dieta , Dislipidemias/epidemiologia , Dislipidemias/terapia , Diagnóstico Precoce , Europa (Continente) , Exercício Físico , Feminino , Promoção da Saúde , Humanos , Estilo de Vida , Masculino , Pessoa de Meia-Idade , Mortalidade/tendências , Obesidade/epidemiologia , Medição de Risco , Abandono do Hábito de Fumar , Espanha/epidemiologia , TraduçõesRESUMO
Based on the two main frameworks for evaluating scientific evidence (SEC and GRADE) European cardiovascular prevention guidelines recommend interventions across all life stages using a combination of population-based and high-risk strategies with diet as the cornerstone of prevention. The evaluation of cardiovascular risk (CVR) incorporates HDL levels and psychosocial factors, a very high risk category, and the concept of age-risk. They also recommend cognitive-behavioural methods (e.g., motivational interviewing, psychological interventions) led by health professionals and with the participation of the patient's family, to counterbalance psychosocial stress and reduce CVR through the institution of positive habits such as a healthy diet, physical activity, smoking cessation, and adherence to treatment. Additionally, public health interventions - such as smoking ban in public areas or the elimination of trans fatty acids from the food chain - are also essential. Other innovations include abandoning antiplatelet therapy in primary prevention and the recommendation of maintaining blood pressure within the 130-139/80-85 mmHg range in diabetic patients and individuals with high CVR. Finally, due to the significant impact on patient progress and medical costs, special emphasis is given to the low therapeutic adherence levels observed. In sum, improving cardiovascular prevention requires a true partnership among the political class, public administrations, scientific and professional associations, health foundations, consumer associations, patients and their families. Such partnership would promote population-based and individual strategies by taking advantage of the broad spectrum of scientific evidence available, from clinical trials to observational studies and mathematical models to evaluate population-based interventions, including cost-effectiveness analyses.
Assuntos
Doenças Cardiovasculares/prevenção & controle , Envelhecimento , Promoção da Saúde , Humanos , Medicina Preventiva , Prevenção Primária , Medição de Risco , Gestão de Riscos , EspanhaRESUMO
La publicación en EE. UU. de la guía de 2013 de American College of Cardiology/American Heart Association para el tratamiento del colesterol elevado ha tenido gran impacto por el cambio de paradigma que supone. El Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología han revisado esa guía, en comparación con la vigente guía europea de prevención cardiovascular y de dislipemias. El aspecto más destacable de la guía estadounidense es el abandono de los objetivos de colesterol unido a lipoproteínas de baja densidad, de modo que proponen el tratamiento con estatinas en cuatro grupos de riesgo aumentado. En pacientes con enfermedad cardiovascular establecida, ambas guías conducen a una estrategia terapéutica similar (estatinas potentes, dosis altas). Sin embargo, en prevención primaria, la aplicación de la guía estadounidense supondría tratar con estatinas a un número de personas excesivo, particularmente de edades avanzadas. Abandonar la estrategia según objetivos de colesterol, fuertemente arraigada en la comunidad científica, podría tener un impacto negativo en la práctica clínica y crear cierta confusión e inseguridad entre los profesionales y quizá menos seguimiento y adherencia de los pacientes. Por todo ello, el presente documento reafirma las recomendaciones de la guía europea. Ambas guías tienen aspectos positivos pero, en general y mientras no se resuelvan las dudas planteadas, la guía europea, además de utilizar tablas basadas en la población autóctona, ofrece mensajes más apropiados para el entorno español y previene del posible riesgo de sobretratamiento con estatinas en prevención primaria (AU)
The publication of the 2013 American College of Cardiology/American Heart Association guidelines on the treatment of high blood cholesterol has had a strong impact due to the paradigm shift in its recommendations. The Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology reviewed this guideline and compared it with current European guidelines on cardiovascular prevention and dyslipidemia management. The most striking aspect of the American guideline is the elimination of the low-density lipoprotein cholesterol treat-to-target strategy and the adoption of a risk reduction strategy in 4 major statin benefit groups. In patients with established cardiovascular disease, both guidelines recommend a similar therapeutic strategy (high-dose potent statins). However, in primary prevention, the application of the American guidelines would substantially increase the number of persons, particularly older people, receiving statin therapy. The elimination of the cholesterol treat-to-target strategy, so strongly rooted in the scientific community, could have a negative impact on clinical practice, create a certain amount of confusion and uncertainty among professionals, and decrease follow-up and patient adherence. Thus, this article reaffirms the recommendations of the European guidelines. Although both guidelines have positive aspects, doubt remains regarding the concerns outlined above. In addition to using risk charts based on the native population, the messages of the European guideline are more appropriate to the Spanish setting and avoid the possible risk of overtreatment with statins in primary prevention (AU)
Assuntos
Humanos , Masculino , Feminino , 35145 , Centers for Disease Control and Prevention, U.S./legislação & jurisprudência , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/metabolismo , Guias de Prática Clínica como Assunto/normas , Prevenção Primária/métodos , Espanha/etnologia , Estados Unidos/etnologia , Centers for Disease Control and Prevention, U.S./história , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/prevenção & controle , Consenso , Prevenção Primária/instrumentaçãoRESUMO
Introducción: La claudicación intermitente ( CI ) es frecuente entre la población occidental, incluida la española; sin embargo, sus características no son bien conocidas. El objetivo del estudio es conocer el perfil de los pacientes españoles con CI. Material y métodos: Estudio prospectivo, observacional, transversal, multicéntrico y no aleatorizado sobre 1.641 claudicantes, divididos en 2 grupos: a) angiología y cirugía vascular (ACV) (n = 920), y b) atención primaria (MAP) (n = 721). Los pacientes fueron sometidos a un cuaderno de recogida de datos (CRD), analítica, índice tobillo/brazo (ITB), cuestionario Walking Impairment Questionaire (WIQ) y cuestionario europeo de calidad de vida (EQ-5D). Resultados: Fueron varones el 75,3%, de 68,3 ± 9,4 años, destacando sobremanera el elevado número de factores de riesgo cardiovascular y enfermedades asociadas (fundamentalmente cardiacas), más frecuente en el grupo ACV. El ITB de la serie 0,66 ± 0,19, inferior en grupo ACV (p = 0,001). Los porcentajes WIQ fueron: daños motores (48,57 ± 20,12), distancia (35,09 ± 25,73), velocidad (36,18 ± 22,83) y escaleras (41,76 ± 27,62), peores en lo relativo a los daños motores (p < 0,001) y distancia (p = 0,007) en el grupo ACV. La puntuación EQ-5D fue 0,57 ± 0,21, sin diferencias entre grupos. Conclusiones: Los pacientes españoles con CI presentan 3 características: alto riesgo cardiovascular, limitada capacidad para el ejercicio e importante reducción de la calidad de vida. Existen diferencias entre grupos, dado que los ACV tratan pacientes con enfermedad más avanzada (AU)
Introduction: Intermittent claudication (IC) is a very prevalent condition in Western countries including the population of Spain. However, little is known about the medical profile and quality of life (QoL) of the IC in Spain. Aim: To determine the clinical characteristics and QoL in a large sample of Spanish patients with IC. Material and methods: An observational, prospective, cross sectional and multicentre study was performed between October 2010 and January 2011, with 625 investigators recruiting 1,641 consecutive patients with claudication. The sample was divided into two groups: a) patients evaluated by vascular surgeons (VS) (n = 920), and b) patients evaluated by general practitioners (GP) (n = 721). Demographical and clinical characteristics, analytical findings (glucose levels and lipid metabolism) and the Ankle-Brachial Index (ABI) were recorded. Each patient included in the study also filled in two questionnaires: the Walking impairment Questionnaire (WIQ) and the European Quality of Life-5 Dimensions (EQ-5D). Results: The population mean age was 68.3 ± 9.4 years; in 75.3% of the cases the patients were males. The presence of risk cardiovascular factors (49.5% of diabetes; 76.9% of hypertension and 65.3% of dyslipemia) and comorbid conditions (in particular, cardiovascular diseases) were high. The mean ABI of the series was 0.66 ± 0.19. Patients in the VS group had more severe IC than patients from GP Group (ABI = 0.63 vs ABI = 0.71, P<0.001). WIQ scores obtained were: a) walking distance = 35.09 ± 25.73; b) walking speed = 36.18 ± 22.83, and c) stair-climbing capacity = 41.76 ± 27.62. We only found significant statistical differences in walking distance between the VS Group and GP Group. The global EQ-5D score was 0,57 ± 0,21. No significant differences were observed between the VS and GP groups (AU)
Conclusions: Spanish patients with IC showed three characteristics: high cardiovascular risk, limited ability to tolerate exercise, and reduction in the quality of their life. There are differences between groups; compared to general practitioners, vascular surgeons treated patients with more advanced disease (AU)
Assuntos
Humanos , Claudicação Intermitente/epidemiologia , Doença Arterial Periférica/epidemiologia , Índice Tornozelo-Braço , Qualidade de Vida , Perfil de Impacto da Doença , Inquéritos e QuestionáriosAssuntos
Doenças Cardiovasculares/prevenção & controle , Anti-Hipertensivos/uso terapêutico , Doenças Cardiovasculares/etiologia , Humanos , Hiperlipidemias/complicações , Hiperlipidemias/tratamento farmacológico , Hipertensão/complicações , Hipertensão/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Prevenção Primária , Fatores de Risco , Prevenção SecundáriaRESUMO
OBJECTIVE: To determine the validity and usefulness of brain natriuretic peptide (BNP) for diagnosing left ventricular dysfunction (LVD). DESIGN: Prospective, descriptive, multi-centred study to validate the diagnostic test. SETTING: Primary care centres in the Community of Madrid, Spain. PARTICIPANTS: Consecutive sample of patients at high risk of presenting with LVD. INTERVENTIONS: Data will be gathered from anamnesis, physical examination, ECG, and chest x-ray to find the risk factor(s) for LVD and the presence or absence of symptoms of congestive heart failure according to the Framingham scale. BNP will be determined at PC clinics in all patients who meet the inclusion criteria, using the "triage BNP test." All patients included in the study will be referred to an echocardiography service for an echocardiogram, which will be the gold standard test. Two independent cardiologists will evaluate the echocardiograph without knowing the BNP values. MAIN MEASUREMENTS: BNP concentrations will be compared against the kind and degree of LVD. ROC curves analysis will test the capacity of BNP to diagnose LVD. Optimal sensitivity and specificity value will be calculated by means of the position on the curve resulting from the minimum distance at the cut-off point for best sensitivity and specificity. Then, sensitivity, specificity, and positive and negative predictive values will be calculated. DISCUSSION: BNP can complement the information provided by other diagnostic tests. It should be included as an important factor in the taking of clinical-therapeutic decisions.
Assuntos
Peptídeo Natriurético Encefálico/sangue , Disfunção Ventricular Esquerda/sangue , Disfunção Ventricular Esquerda/diagnóstico , Humanos , Estudos Multicêntricos como Assunto , Atenção Primária à Saúde , Estudos Prospectivos , Reprodutibilidade dos TestesRESUMO
No disponible
Assuntos
Humanos , Adulto , Feminino , Idoso , Masculino , Pessoa de Meia-Idade , Estilo de Vida , Atenção Primária à Saúde , Anti-Hipertensivos , Doenças Cardiovasculares , Estudos de Coortes , Fatores Etários , Hipercolesterolemia , Tabagismo , Prevenção Primária , Fatores Sexuais , Hipolipemiantes , Fatores de Risco , HipertensãoAssuntos
Doenças Cardiovasculares/prevenção & controle , Adulto , Fatores Etários , Idoso , Anti-Hipertensivos/uso terapêutico , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/mortalidade , Estudos de Coortes , Feminino , Humanos , Hipercolesterolemia/complicações , Hipertensão/complicações , Hipertensão/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Estilo de Vida , Masculino , Pessoa de Meia-Idade , Atenção Primária à Saúde , Prevenção Primária , Fatores de Risco , Fatores Sexuais , Fumar/efeitos adversos , Prevenção do Hábito de FumarRESUMO
La insuficiencia cardíaca es un importante problema de salúd pública que afecta a una proporción creciente de la población, sobre todo personas mayores, generando una gran morbimortalidad y un elevado coste sociosanitario, frente al que es preciso adoptar estrategias preventivas adecuadas (AU)
Assuntos
Humanos , Atenção Primária à Saúde/métodos , Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/prevenção & controle , Isquemia Miocárdica/complicações , Hipertensão/complicações , Espanha , Disfunção Ventricular/diagnóstico , Fatores de Risco , Prevenção Primária/métodos , Índice de Gravidade de Doença , Sensibilidade e Especificidade , Prognóstico , Eletrocardiografia , Insuficiência Cardíaca/etiologiaRESUMO
En el presente artículo nos centraremos en el mantenimiento y la monitorización de esquema terapéutico básico en el paciente con insuficiencia cardíaca. Tratar adecuadamente al paciente con esta afección depende inicialmente de realizar un correcto diagnóstico clínico preciso de la insuficiencia cardíaca, pero también del tipo de fallo diastólico o sistólico, de los factores causales y precipitantes de la situación de la insuficiencia cardíaca y también de la comorbilidad que con frecuencia acompaña a los pacientes con esta afección (AU)
Assuntos
Humanos , Insuficiência Cardíaca/terapia , Prognóstico , Dieta Hipossódica , Terapia por Exercício , Peptidil Dipeptidase A , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Diuréticos/uso terapêutico , Antagonistas Adrenérgicos beta/uso terapêutico , SeguimentosAssuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Hipertensão/tratamento farmacológico , Propanolaminas/uso terapêutico , Celiprolol , Avaliação de Medicamentos , Tolerância a Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
Three cases of obstructive sleep apnea syndrome are reported. The diagnosis was suspected by the family physician and was later documented by the pertinent polygraphic sleep recordings. The patients were middle aged obese males who consulted for minor problems and reported daytime hypersomnolence, loud snoring and startled sleep. The important role of the primary care physician in the suspicion of this syndrome is stressed, as well as the relevance of early diagnosis which permits adequate therapy.